OCA
ROIV icon

Octagon Capital Advisors’s Roivant Sciences ROIV Stock Holding History

Octagon Capital Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,494,000
Closed -$28M – 63
2023
Q4 		$28M Sell
2,494,000
-1,873,000
-43% -$18.3M 4.48% 8
2023
Q3 		$51M Buy
4,367,000
+463,000
+12% +$5.23M 7.84% 2
2023
Q2 		$39.4M Hold
3,904,000
– – 5.48% 5
2023
Q1 		$28.8M Buy
+3,904,000
New +$32.1M 4.15% 7

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Octagon Capital Advisors's ROIV Position: Q1 2024 in Review

Octagon Capital Advisors sold out of Roivant Sciences (ROIV) in Q1 2024, closing a stake of 2,494,000 shares — an estimated $28M sold.

Octagon Capital Advisors first reported a position in ROIV in Q1 2023 and held it in 4 quarters. The position peaked at $51M in Q3 2023. 259 funds tracked by Wall St. Rank hold ROIV as of Q1 2024.

  • Octagon Capital Advisors reported no remaining Roivant Sciences position as of Q1 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 2,494,000 Roivant Sciences shares in Q1 2024, an estimated $28M.
  • Octagon Capital Advisors first reported a position in Roivant Sciences in Q1 2023 and held it in 4 quarters.
  • Octagon Capital Advisors's Roivant Sciences position peaked at $51M in Q3 2023.
  • 259 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2024.

Based on Octagon Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.